Deutsche Bank Analysts Give Bayer (FRA:BAYN) a €82.00 Price Target
Deutsche Bank set a €82.00 ($96.47) price objective on Bayer (FRA:BAYN) in a report published on Monday morning, Borsen Zeitung reports. The firm currently has a buy rating on the healthcare company’s stock.
A number of other equities analysts have also weighed in on the stock. Warburg Research set a €81.00 ($95.29) price target on shares of Bayer and gave the stock a neutral rating in a research report on Friday, September 11th. Independent Research set a €59.00 ($69.41) price target on shares of Bayer and gave the stock a neutral rating in a research report on Wednesday, August 5th. Berenberg Bank set a €76.00 ($89.41) target price on shares of Bayer and gave the stock a buy rating in a research report on Tuesday, August 11th. Baader Bank set a €105.00 ($123.53) target price on shares of Bayer and gave the stock a buy rating in a research report on Tuesday, August 4th. Finally, Barclays set a €80.00 ($94.12) target price on shares of Bayer and gave the stock a buy rating in a research report on Tuesday, August 4th. Five research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of €81.19 ($95.51).
BAYN opened at €56.46 ($66.42) on Monday. Bayer has a 1-year low of €91.58 ($107.74) and a 1-year high of €123.82 ($145.67). The company has a 50 day simple moving average of €56.39 and a two-hundred day simple moving average of €59.52.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Read More: Why do earnings reports matter?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.